News 

About IAPACEducationAdvocacyConferencesWhat's NewPublicationsJoin IAPACContact UsLinksMain Page
 

Norvir Advisory

International Association of Physicians in AIDS Care

Document: IAPAC Norvir Advisory
File: INA100B
Effective: 9/1/98

A. Description

The IAPAC Norvir Advisory is a cyberspace publication of the International Association of Physicians in AIDS Care (IAPAC). The primary publication venue of the IAPAC Norvir Advisory is the IAPAC Web site (www.iapac.org).

B. Mission

The mission of the IAPAC Norvir Advisory is to provide a forum for the provision of reliable information on the switch from Norvir capsules to Norvir liquid and/or other appropriate antivirals that maximizes the survival options of people with HIV disease.

All medical advice and information will be provided by physicians and other healthcare professionals who have extensive experience in the management of HIV disease and/or the use of ritonavir in clinical trials and/or in patient management.

C. Access to and Distribution of the IAPAC Norvir Advisory

Individuals and organizations with Internet access capabilities can access the IAPAC Norvir Advisory and register in the IAPAC Norvir Advisory majordomo for automatic e-mail broadcast announcements of the titles of new materials uploaded on the IAPAC Norvir Advisory. IAPAC will also provide print copies of IAPAC Norvir Advisory materials by fax or direct mail to "Eligible Providers." For the purpose of this document, an "Eligible Provider" is a physician who is prescribing ritonavir or a pharmacist who dispenses ritonavir prescriptions, and who does not have access to the Internet." An "Eligible Provider" may request print copies of the IAPAC Norvir Advisory by completing and faxing or mailing the Eligible Provider Enrollment Request.

D. Copyright Restrictions.

The IAPAC Norvir Advisory © 1998 by the International Association of Physicians in AIDS Care (IAPAC). Reproduction of all or any part of material contained in the INA by any process, including photocopying or entering such material into a computer, without prior written permission of an officer of IAPAC is expressly prohibited.

The purpose of this restriction is to protect the integrity of the materials in the IAPAC Norvir Advisory from modification or alternation when such modification or alteration could result in harm to a patient, that patient's physician and pharmacist, the authors of the material, and the International Association of Physicians in AIDS Care. The Internet can be a valuable resource for people with HIV/AIDS and other challenging diseases, and for the physicians and other healthcare professionals who care for them. However, the facility of a third party to take comments out of context, or edit them in any way, diminishes the reliability of any Web site document. IAPAC therefore recommends that anyone basing a medical decision on Web site information received from a third party, to download the original article directly from the site on which it is featured.

All members of the association can request prior written permission to duplicate any IAPAC Norvir Advisory materials by completing the IAPAC Member Print/Computer Reproduction Request form and returning it to IAPAC by fax or mail. Non-IAPAC members should request prior written authorization by completing the Non-Member Print/Computer Reproduction Request form and returning it to IAPAC by fax or mail.

E. Editorial Policy

The medical information and advice in the IAPAC Norvir Advisory is under the review on the IAPAC Norvir Advisory Committee and is subject to the approval of the committee chair. Due to the urgency of providing much of the medical information and advice in the IAPAC Norvir Advisory, all members of the IAPAC Norvir Advisory Committee are given 48 hours to review and comment on original materials developed exclusively for the IAPAC Norvir Advisory prior to being uploaded. Committee members are asked to provide a written critique of such material which will be published as a supplement to such material. Special features in the IAPAC Norvir Advisory that are designated as consensus documents must have a 75 percent approval of the committee members, and all dissenting opinions will be published as a supplement to the document.

Links to other Web sites are also subject to committee review. correspondence between IAPAC and any pharmaceutical company, pharmaceutical distributor, and others providing advice on the use of ritonavir and/or other antiviral agents to be used in lieu of ritonavir will be published in the IAPAC Norvir Advisory and will be a permanent record on the request for information and the response to such request.

All material, including, letters, and answers to questions submitted to the IAPAC Norvir Advisory and published in the IAPAC Norvir Advisory represents the opinions of the authors and does not necessarily reflect the official policy of the International Associations of Physicians in AIDS Care or the institutions with which the author may be affiliated.

The IAPAC Norvir Advisory is supported by an unrestricted educational grant from Abbott Laboratories. Neither Abbott Laboratories nor any organization retained or contracted by Abbott Laboratories has any direct or indirect influence on the editorial policy of the IAPAC Norvir Advisory or the policies of International Association of Physicians in AIDS Care.

Since Abbott Laboratories manufactures ritonavir, the medical department of Abbott Laboratories and/or scientists employed by Abbott Laboratories may be requested to comment on medical and/or scientific data about ritonavir that are referenced in medical and scientific reports considered for publication in the IAPAC Norvir Advisory. Requests for the review of such medical or scientific information shall be made in writing by IAPAC and the written response to such data will be included with the published report in the IAPAC Norvir Advisory as a permanent record of the request and response. Abbott Laboratories is also invited to submit written comments about any materials published in the IAPAC Norvir Advisory and such comments will be included as a permanent record in a subsection of published medical or scientific reports.

Posted 9/2/98

Notice: This is an IAPAC initiative that is under the sole direction of the IAPAC Norvir Advisory Committee. Contents of the Norvir Advisory section of the IAPAC Web site are subject to the approval of the chair of the advisory committee and will reflect the recommendations of the committee members. Abbott Laboratories has no input in the content of the Norvir Advisory section of the IAPAC Web site.